| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0165-2478(97)00075-8 |
| P698 | PubMed publication ID | 9232436 |
| P50 | author | Timothy N C Wells | Q55182082 |
| P2093 | author name string | A E Proudfoot | |
| C A Power | |||
| C Plater-Zyberk | |||
| A J Hoogewerf | |||
| P2860 | cites work | Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES | Q24304260 |
| Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor | Q24680555 | ||
| Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor | Q28297700 | ||
| RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis | Q28307643 | ||
| Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis | Q34129985 | ||
| Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis | Q34224384 | ||
| Collagen autoimmune arthritis | Q34258934 | ||
| Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8 | Q36362602 | ||
| Properties of the novel proinflammatory supergene "intercrine" cytokine family. | Q37357898 | ||
| Collagen arthritis as a relevant model for rheumatoid arthritis | Q40338367 | ||
| Cytokine expression in chronic inflammatory disease | Q40409049 | ||
| Chemokines, leukocyte trafficking, and inflammation | Q40502969 | ||
| Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis | Q40587405 | ||
| Collagen arthritis--what can it teach us? | Q40700344 | ||
| CC chemokines in allergic inflammation | Q40747734 | ||
| Cloning and characterization of human chemokine receptors. | Q41077955 | ||
| Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. | Q41209333 | ||
| Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. | Q41229926 | ||
| Representative sample of rheumatoid synovium: a morphometric study | Q42088217 | ||
| Morphometric comparison of synovium from patients with osteoarthritis and rheumatoid arthritis | Q42842256 | ||
| The role of cytokines in the pathogenesis of rheumatoid arthritis | Q69112410 | ||
| Anti-CD5 therapy decreases severity of established disease in collagen type II-induced arthritis in DBA/1 mice | Q71662354 | ||
| Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells | Q71708739 | ||
| Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo | Q71803587 | ||
| P433 | issue | 1-3 | |
| P304 | page(s) | 117-120 | |
| P577 | publication date | 1997-06-01 | |
| P1433 | published in | immunology Letters | Q15766068 |
| P1476 | title | Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice | |
| P478 | volume | 57 |
| Q34025058 | A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo |
| Q57227924 | A key role for ICAM-1 in generating effector cells mediating inflammatory responses |
| Q48086566 | A natural CCL5/RANTES variant antagonist for CCR1 and CCR3. |
| Q34389532 | A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation |
| Q34130186 | Amelioration of rat adjuvant-induced arthritis by Met-RANTES. |
| Q45042000 | Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis. |
| Q33693006 | Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease |
| Q34082362 | Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis |
| Q45663708 | Blocking CC chemokine receptor (CCR) 1 and CCR5 during herpes simplex virus type 2 infection in vivo impairs host defence and perturbs the cytokine response |
| Q50779652 | CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. |
| Q43913450 | CC chemokine receptor (CCR)-2 prevents arthritis development following infection by Mycobacterium avium |
| Q37689783 | CCR5 antagonists: the answer to inflammatory disease? |
| Q42605598 | CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases |
| Q34652416 | CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway |
| Q47753720 | Cellular assays of chemokine receptor activation |
| Q35528569 | Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies |
| Q43634198 | Chemokine antagonist infusion promotes axonal sparing after spinal cord contusion injury in rat. |
| Q35553008 | Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis |
| Q54745308 | Chemokine receptor CCR5 is not required for development of experimental autoimmune gastritis. |
| Q33538287 | Chemokine receptors and their role in leukocyte activation. |
| Q35048804 | Chemokine receptors in inflammation: an overview |
| Q34575325 | Chemokine receptors: multifaceted therapeutic targets |
| Q34051768 | Chemokines and chemokine receptors in arthritis |
| Q28200068 | Chemokines and disease |
| Q29618886 | Chemokines and leukocyte traffic |
| Q34605411 | Chemokines as novel therapeutic targets in inflammatory diseases |
| Q35553416 | Chemokines in joint disease: the key to inflammation? |
| Q44110120 | Definition, function and pathophysiological significance of chemokine receptors |
| Q22253325 | Differential activation of CC chemokine receptors by AOP-RANTES |
| Q24807287 | Differential binding of chemokines to macrophages and neutrophils in the human inflamed synovium |
| Q39893068 | Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer |
| Q36371879 | Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis |
| Q82455857 | Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis |
| Q40643961 | Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis |
| Q34896763 | Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells |
| Q37184794 | G protein betagamma subunits as targets for small molecule therapeutic development |
| Q37167274 | G protein βγ subunits: central mediators of G protein-coupled receptor signaling |
| Q28375207 | Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1 |
| Q34658695 | In silico studies on DARC. |
| Q38618883 | Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review |
| Q47253731 | Inhibition of generation of cytotoxic T lymphocyte activity by a CCL19/macrophage inflammatory protein (MIP)-3beta antagonist |
| Q47393101 | Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. |
| Q33695770 | Interfering with chemokine networks--the hope for new therapeutics |
| Q59042033 | Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement |
| Q34571301 | Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection. |
| Q57790213 | Met-RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo |
| Q35014330 | Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis |
| Q34309745 | New therapies in development for autoimmune diseases: their rationale for combination treatment |
| Q33611094 | Opportunities for novel therapeutic agents acting at chemokine receptors |
| Q84534177 | Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody |
| Q41603563 | Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo |
| Q37383845 | Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model |
| Q46179973 | Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation |
| Q85118805 | RANTES Deficiency Attenuates Autoantibody-Induced Glomerulonephritis |
| Q47140595 | RANTES/CCL5 Induces Collagen Degradation by Activating MMP-1 and MMP-13 Expression in Human Rheumatoid Arthritis Synovial Fibroblasts. |
| Q36309612 | RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. |
| Q24291028 | Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells |
| Q57019193 | Recent developments in modulating chemokine networks |
| Q35066724 | Response of chemokine antagonists to inflammation in injured spinal cord |
| Q36069520 | Reversing the autoimmune condition: experience with experimental autoimmune gastritis. |
| Q28083593 | Review: basics of drug development in rheumatology |
| Q35024052 | Role of CCL5 (RANTES) in viral lung disease. |
| Q90642824 | Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis |
| Q38188747 | Role of chemokines in proteinuric kidney disorders |
| Q37342574 | Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation |
| Q47882990 | Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor |
| Q35031917 | Strategies for chemokine antagonists as therapeutics |
| Q38647749 | Successes and failures of chemokine-pathway targeting in rheumatoid arthritis |
| Q24793032 | Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8 |
| Q35825040 | Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. |
| Q47434283 | The Type 1 Diabetes-Resistance Locus Idd22 Controls Trafficking of Autoreactive CTLs into the Pancreatic Islets of NOD Mice |
| Q36096959 | The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis |
| Q47973433 | The delta32 deletion of CCR5 receptor in rheumatoid arthritis |
| Q79366300 | The effect of infliximab on chemokines in patients with rheumatoid arthritis |
| Q28570154 | The effects of interleukin-18 on rat articular chondrocytes: a study of mRNA expression and protein synthesis of proinflammatory substances |
| Q39850146 | The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking |
| Q33850741 | The importance of being receptive |
| Q60311707 | The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells |
| Q41945153 | The multiple chemokine-binding bovine herpesvirus 1 glycoprotein G (BHV1gG) inhibits polymorphonuclear cell but not monocyte migration into inflammatory sites. |
| Q36992526 | The role of chemokines in leucocyte-stromal interactions in rheumatoid arthritis |
| Q42487146 | VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. |
| Q28742993 | Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis |
| Q79151474 | [Chemokine--possible new options for the treatment of multiple sclerosis] |
Search more.